Controlled Substances Act Violations in Florida, Maryland, New York and Washington State
Cardinal Health agreed to pay $34 million in civil penalties to resolve allegations that it failed to report to the U.S. Drug Enforcement Administration (DEA) suspicious orders of Class II controlled substances (including oxycodone) by pharmacies located in Florida and Maryland from January 2009 to May 2012. The settlement also resolved a federal civil investigation into Cardinal Health’s failure to maintain adequate records concerning controlled substances in Washington State. Separately, Kinray LLC, a pharmaceutical distributor owned by Cardinal Health, agreed to pay $10 million to resolve allegations that it failed to report suspicious orders of oxycodone or hydrocodone by New York-area pharmacies between January 2011 and May 2012. As part of the settlement, Kinray accepted responsibility for failing to inform the DEA.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement
|Cardinal Health, Inc.||$44,000,000|